Insight into how Toxoplasma gondii triggers immune response in its host
Long-term use of a macrolide antibiotic may reduce the frequency of exacerbations in patients with moderate to severe chronic obstructive pulmonary disease (COPD) by as much as 35 percent, according to a London-based study. “Our results show a significant effect of low-dose macrolide therapy, reducing exacerbation frequency and severity with moderate to severe COPD,” wrote
Full Post: Long-term use of a macrolide antibiotic reduce COPD exacerbations, raise questions
Researchers provide insight into how Toxoplasma gondii, a common parasite of people and other animals, triggers an immune response in its host.
The report will appear online on January 19th in The Journal of Experimental Medicine .
A strong immune response spares T. gondii -infected hosts from deadly infection-an event that may also benefit the parasite, which relies on survival of the host to ensure its own transmission. But how the infected host elicits an immune response isn’t completely understood. Like many other parasites, T. gondii resides within specialized vesicles inside infected host cells, but the process by which peptides from the trapped bugs are processed by infected cells and presented to killer T cells is mysterious.
Here, Romina Goldszmid and her colleagues at the National Institutes of Health in Bethesda use T. gondii infections in mice to study how portions of the parasitic proteins escape the vesicle in a process known as cross-presentation. They find that the parasite gets noticed by the immune system when the membrane of the bug-containing vesicle fuses to the endoplasmic reticulum - an organelle normally involved in presenting pathogens to T cells - allowing a swap of parasitic peptides.
Our immune cells have an amazingly intricate recognition system to detect invading pathogens. Often, the intricacies have overwhelmed scientists who want to know exactly what gives an alarm signal to T cells, a class of white blood cells that recognizes invaders. “For some pathogens like the flu, the components that trigger a host immune response
Full Post: Scientists pinpoint immune-system targets in complex pathogens
Bavituximab, an anti-viral drug developed by UT Southwestern Medical Center researchers, shows promise as a new strategy to fight viral diseases, including potential bioterrorism agents. In a study appearing in the December issue of Nature Medicine , groups of guinea pigs infected with a virus similar to Lassa fever virus recovered from the fatal disease
Full Post: Researchers develop new strategy for broad spectrum anti-viral drugs
Hundreds of millions of people, mainly in developing countries, are disabled by infectious diseases, according to the World Health Organization. More than 12 million people in 88 countries are infected with leishmaniasis, a parasitic disease spread by the bite of infected sand flies. Nearly 2 million new cases are reported and about 70,000 people die
Full Post: Researchers hunt for new drugs for Leishmaniasis
Forget what’s number one at the box office this week. The most exciting new film features the intricate workings of the body, filmed by scientists using ground-breaking technology. For the first time in Australia, scientists at Sydney’s Centenary Institute have filmed an immune cell becoming infected by a parasite and followed the infection as it
Full Post: Scientists film immune cell becoming infected by a parasite
In a November 16 advance, online publication of the journal Nature, the researchers say their discovery revamps common beliefs about how such potentially lethal infections may be ravaging the brain and suggests the possibility of new treatments. “This is a paradigm shift in how we think about some forms of meningitis and possibly other infections,”
Full Post: Scientists discover new cause of fatal brain injury from acute viral meningitis